Officer Yen Kristen sold 95,500 shares ($6.4M) in 10 transactions on 2025-03-27, reducing stake by 77.2% to 28,143 shares.
Yen Kristen executed 10 separate sales totaling 95,500 shares for $6,376,788.68 at prices ranging from $65.97 to $72.64, a blended average of $66.77. This represents a 77.2% reduction in holdings over a single day, leaving only 28,143 shares post-transaction. The timing coincides with the stock trading near its 52-week high of $71.99 (current price $71.45 is -0.8% from that peak) and follows a dramatic 30-day surge of +46.4% and 90-day gain of +59.0%. Despite the company's strong revenue growth of +138.8% year-over-year, SOLENO Therapeutics remains deeply unprofitable with a net loss of $-76,616,000 in its most recent full fiscal year, and the latest quarter shows minimal revenue of $1,000.00. The substantial divestiture at elevated prices during a period of strong momentum warrants close attention to whether the insider's view on the risk-reward profile has shifted.